Real world initiation of newly funded empagliflozin and dulaglutide under special authority for patients with type 2 diabetes in New Zealand
Prioritised access for SGLT2i/GLP1RA appears to be associated with a reduced health equity gap for Māori and Pacific patients with T2D in NZ, but work is required to improve prescribing for patients with CVRD.
Authors
- Ryan Paul (ORCID: https://orcid.org/0000-0002-1579-3870)
- Jo Scott‐Jones
- Rinki Murphy (ORCID: https://orcid.org/0000-0002-0043-2423)
- Leanne Te Karu (ORCID: https://orcid.org/0000-0002-8645-3937)
- Penny Clark
- Ross Lawrenson (ORCID: https://orcid.org/0000-0003-0437-8839)
- Mark Rodrigues (ORCID: https://orcid.org/0000-0002-4507-6872)
- Rāwiri Keenan (ORCID: https://orcid.org/0000-0001-8312-8525)
- Han Ming Gan (ORCID: https://orcid.org/0000-0001-7987-738X)
- Lynne Chepulis (ORCID: https://orcid.org/0000-0002-9661-4669)
- Timothy W Kenealy (ORCID: https://orcid.org/0000-0001-6002-4766)
- Sara Mustafa (ORCID: https://orcid.org/0000-0001-5902-5622)
- Allan Moffitt
Institutions
- University of Auckland (NZ)
- Clinical Trials New Zealand (NZ)
- Waikato District Health Board (NZ)
- New Zealand Christians in Science (NZ)
- University of Waikato (NZ)
- Manaaki Whenua – Landcare Research (NZ)
Publication Details
- Journal
- BMC Health Services Research
- Published
- 2025-03-26
- DOI
- https://doi.org/10.1186/s12913-025-12601-3
- Citations
- 5
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 6.47
Funders
- Health Research Council of New Zealand